Tag Archives: dolutegravir

IAS 2019: While plans for HIV control innovations accelerate, community input remains an afterthought

By on .

MEXICO CITY – “What HIV has pointed out is that building it does not make them come,” Ambassador Dr. Deborah Birx noted at an opening night press event that highlighted persisting gaps in HIV testing, treatment, prevention access across the globe. When services don’t reach clients and communities, she said, people offering them have to […]

Targeting the pediatric HIV treatment gap, speeding drug development, imagining a world of equitable treatment access, the Medicines Patent Pool aims for breakthroughs

By on .

An event last week launching the Pediatric treatment Initiative “to get kids the medicines they need,” included the news of a commitment to double the number of children on treatment with support from the President’s Emergency Plan For AIDS Relief within the next two years. With a continued gap that sees an estimated two million […]

Medicines Patent Pool, drugmaker agreement set to expand access to new antiretroviral

By on .

Dolutegravir agreement continue collaboration between British company and Unitaid-launched treatment access organization With a high barrier to drug-resistance, low production costs, low dosing and a potential for pediatric use, the new HIV drug dolutegravir, approved by the U.S. Food and Drug Administration in August, and for use among adults and adolescents by the European Medicines […]